/
Oncology
Non-Small Cell Lung Carcinoma
46
Pipeline Programs↗
35
Active Trials↗
33
Companies Involved↗
Non-Small Cell Lung Carcinoma is a moderately active landscape with 46 programs across 33 companies. The most active players are Merck & Co., Pfizer, AstraZeneca. 16 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical18
Phase 1
No programs
Phase 212
Phase 316
Approved
No programs
Analysis
Modality Breakdown
39programs
Small molecule2359%
Monoclonal antibody1128%
Antibody–drug conjugate410%
Gene therapy13%
Modality classified for 93% of 46 pipeline programs.
Analysis
Trial Status
64
clinical trials
Recruiting18 · 28%
Completed16 · 25%
Terminated8 · 13%
Active, not recruiting8 · 13%
Not yet recruiting8 · 13%
Unknown status4 · 6%
Other2 · 3%
Clinical Trials
Trial Activity
64 trials
Page 1 of 5
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)